# Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

> **NCT05401279** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Urothelial Carcinoma Bladder
- PD-1 Inhibitor

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05401279
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-04
- **Final completion:** 2025-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401279, "Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05401279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*